Global End-Stage Renal Disease Market

End-Stage Renal Disease (ESRD) Market Size, Share, Growth Analysis, By Treatment(Dialysis, Kidney and Transplantation), By End-user(hospitals and clinics, and home care settings) - Industry Forecast 2024-2031

Report ID: SQMIG35J2054 | Region: Global | Published Date: March, 2024
Pages: 219 | Tables: 61 | Figures: 75

End-Stage Renal Disease (ESRD) Market Insights

Global End-Stage Renal Disease Market size was valued at USD 99.2 Billion in 2022 and is poised to grow from USD 112.2 Billion in 2023 to USD 300.38 Billion by 2031, at a CAGR of 13.10% during the forecast period (2024-2031).

The increasing number of individuals suffering from kidney failure and the introduction of advanced medical devices, such as low-maintenance dialysis equipment and artificial kidneys, are key drivers of this market. Chronic Kidney Disease (CKD) is a major cause of kidney failure, often resulting from conditions that lead to reduced kidney function. CKD can gradually develop over time and eventually progress to ESRD, also known as kidney failure. Factors such as hypertension, diabetes, smoking, and the aging population contribute to the development of ESRD, with diabetes being the most common cause and hypertension being the second-most frequent cause. Treatment options for ESRD/CKD include kidney transplantation or dialysis to sustain life. CKD has a high incidence rate globally, with approximately 10% of the global population suffering from the condition, leading to millions of deaths each year. The geriatric population in developing countries, such as China and India, is particularly affected. The number of patients requiring kidney transplants or dialysis is increasing at a rate of 5-7% annually. The prevalence of CKD is higher in women than men, and the rising number of individuals with hypertension and diabetes further contributes to the growth of the market. Diabetes is the primary cause of advanced kidney disease, followed by hypertension, affecting approximately 1 billion individuals worldwide. Baxter, a prominent company in this market, has announced strategic initiatives to enhance operational effectiveness and innovation, including spinning out their renal care and acute treatments global business units into a separate organization.

Regions like Africa, China, the Rest of Asia Pacific, the U.S., Taiwan, Japan, Germany, France, and Belgium have observed a high prevalence of ESRD in recent years. In the U.S., around 80 million people, or 1 in 3 adults, are at risk of CKD, making it the ninth leading cause of death. Developing countries like China and India are projected to witness an increase in cases of renal failure, particularly among the elderly population. The market growth is further supported by technological advancements in the treatment of renal failure. For example, the approval of human clinical trials for the Wearable Artificial Kidney 2.0 by the U.S. FDA in 2014 showcases the development of innovative blood purification technologies for kidney failure patients. The presence of numerous hospitals and a well-developed healthcare infrastructure in the U.S. also contributes to market growth. With a significant number of hospital admissions for acute kidney injury (AKI), there is a growing demand for dialysis and transplantation. Additionally, the number of dialysis clinics and treatment centers is increasing, with approximately 7,500 dialysis clinics currently operating in the U.S.

US End-Stage Renal Disease (ESRD) Market is poised to grow at a sustainable CAGR for the next forecast year.

Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.



End-Stage Renal Disease Market size was valued at USD 99.2 Billion in 2022 and is poised to grow from USD 112.2 Billion in 2023 to USD 300.38 Billion by 2031, at a CAGR of 13.10% during the forecast period (2024-2031).

The end-stage renal disease (ESRD) market is characterized by the presence of several companies striving to develop innovative treatment solutions. These companies focus on research and development activities to introduce technologically advanced products in the market. Additionally, strategic initiatives such as partnerships, collaborations, and acquisitions are commonly observed in the industry. The competitive environment is driven by the pursuit of enhancing operational effectiveness, accelerating innovation, and improving patient outcomes. Market players aim to gain a competitive edge by offering comprehensive solutions and expanding their geographical presence. 'Fresenius Medical Care AG & Co. KGaA (Germany)', 'Baxter International Inc. (US)', 'Davita Inc. (US)', 'B. Braun Melsungen AG (Germany)', 'Nikkiso Co., Ltd. (Japan)', 'NxStage Medical, Inc. (US)', 'Asahi Kasei Corporation (Japan)', 'Rockwell Medical, Inc. (US)', 'Cantel Medical Corporation (US)', 'Medtronic plc (Ireland)', 'Terumo Corporation (Japan)', 'Nipro Corporation (Japan)', 'Kawasumi Laboratories, Inc. (Japan)', 'Stryker Corporation (US)', 'Allmed Medical Corporation (China)', 'Fresenius Kabi AG (Germany)', 'Dialysis Clinic, Inc. (US)', 'Toray Medical Co., Ltd. (Japan)', 'Medivators Inc. (US)', 'Quanta Dialysis Technologies Ltd. (UK)'

One significant driver in the end-stage renal disease market is the increasing prevalence of chronic kidney disease (CKD), particularly driven by conditions such as hypertension and diabetes. With a high number of individuals worldwide being affected by these chronic diseases, the risk of developing CKD and eventually progressing to ESRD rises. This escalating patient population necessitates the demand for effective treatment options, including kidney transplantation or dialysis, thereby propelling the growth of the market.

One key market trend in the end-stage renal disease (ESRD) market is the increasing adoption of home-based dialysis treatments. This trend is driven by the desire to improve patient convenience, reduce healthcare costs, and enhance patient outcomes. Home dialysis therapies, such as peritoneal dialysis and home hemodialysis, offer greater flexibility, independence, and the ability to receive treatment in the comfort of one's own home. This shift towards home-based dialysis is being supported by advancements in technology, improved training programs, and favorable reimbursement policies, thus driving the growth of the market.

The United States is a dominating region in the end-stage renal disease (ESRD) market. It has a well-developed healthcare infrastructure and a significant number of hospitals, including community hospitals and federal government hospitals. The United States also has a large number of dialysis clinics, approximately 7,500 currently, catering to the increasing prevalence of ESRD. The country witnesses a high incidence of CKD and ESRD, with around 80 million people, or 1 in 3 American adults, at risk of CKD. This makes CKD the ninth leading cause of death in the United States. The presence of advanced medical technologies, research and development activities, and favorable reimbursement policies contribute to the dominance of the United States in the ESRD market.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.


Feedback From Our Clients

Global End-Stage Renal Disease Market

Product ID: SQMIG35J2054